Serine/Threonine TGF b Signalling & Hormone Basics

Serine/Threonine Receptor Kinases – Focus on the TGF-β Pathway

  • Context & Scope

    • Last receptor-kinase “type” covered (others already include receptor tyrosine kinases, etc.).

    • Several additional signalling pathways will be discussed later, but no new receptor-kinase “families.”

Dual Nature of TGF-β Family Ligands
  • TGF-β family ligands can either activate or inhibit cell functions depending on the responding cell-type.

    • Instructor will revisit this nuance during cell-cycle lectures.

Canonical “Activation” Outcomes (when TGF-β is stimulatory)
  • Cell proliferation.

  • Apoptosis (programmed cell death) – controlled removal of cells.

  • Cell specialization / differentiation (e.g., “little cell” → neuron).

  • Crucial roles in embryonic development because of extensive differentiation requirements.

Receptor Architecture & Early Signal Steps
  • Two distinct transmembrane serine/threonine kinase receptors participate:

    1. Type I receptor (purple tail in slide).

    2. Type II receptor.

  • Ligand binding choreography

    • Both receptors bind the same TGF-β ligand simultaneously.

    • The Type II receptor is constitutively active → phosphorylates the Type I receptor.

    • Activated Type I receptor then phosphorylates cytoplasmic R-SMAD proteins.

SMAD Cascade & Nuclear Events
  • Phosphorylated R-SMAD (referred to as “R SMAD” in lecture) dimerizes with SMAD4.

  • The R-SMAD/SMAD4 complex translocates to the nucleus → modulates transcription of target genes.

Cancer-Related Mutations in TGF-β & Other Growth-Factor Pathways
  • General point: Disruptions in growth-factor signalling are oncogenic.

    • First oncogene discovered: a mutation in the RASRAS gene (historical landmark).

  • EGF-receptor (RTK) mutations

    • Associated cancers: breast carcinoma, glioblastoma (glial-cell tumors), fibrosarcoma (long-bone connective-tissue tumors).

  • TGF-β pathway lesion statistics

    • Type I receptor mutations present in ≈13\approx \tfrac{1}{3} of ovarian cancers.

    • Type II receptor mutations linked to colorectal cancers.

    • SMAD4 mutations observed in ≈50%\approx 50\% of pancreatic cancers.

  • Implication: Proper serine/threonine receptor-kinase signalling is critical for cell-cycle regulation and controlled cell division.


Hormone Fundamentals (Preview for Upcoming Pathways)

Production, Circulation & Half-Life
  • Hormones are synthesized in endocrine glands → released into bloodstream.

  • Once in blood, lifetime varies widely:

    • Epinephrine (adrenaline): seconds (short bursts; avoids prolonged “fight-or-flight”).

    • Insulin: hours (sustained glycaemic control).

    • Steroid hormones (lipid-based): potentially days (due to carrier proteins & lipid solubility).

“Target” Cell Definition
  • A tissue is a target tissue for a hormone if its cells possess the specific receptor for that hormone → receptor presence = responsiveness.

Broad Chemical Categories of Hormones
  • Amino-acid–based / peptide / protein hormones.

  • Lipid-based hormones (steroids derived from cholesterol).

Adrenergic Hormones (brief mention)
  • Instructor alludes to upcoming detail on adrenergic hormones (epinephrine, norepinephrine) that bind adrenergic receptors; specifics to follow in later slides.


Key Terms & Concepts (Quick Reference)

  • Serine/Threonine Receptor Kinase: Receptor whose cytoplasmic domain phosphorylates substrates on serine or threonine residues.

  • TGF-β (Transforming Growth Factor-β): Multifunctional cytokine family with context-dependent effects.

  • R-SMAD: Receptor-regulated SMAD (direct substrate of Type I receptor).

  • SMAD4: Common-mediator SMAD that partners with R-SMAD.

  • Apoptosis: Programmed cell death; contrasted with necrosis.

  • Oncogene: Mutated gene promoting cancer (e.g., RASRAS).


Conceptual Connections & Significance

  • The TGF-β/SMAD pathway illustrates how serine/threonine receptor kinases translate extracellular cues into gene-expression programs.

  • Cross-talk with other pathways (RTKs, GPCRs) coordinates proliferation vs. differentiation vs. apoptosis.

  • Mutational hotspots in receptors or SMADs underscore therapeutic targets in oncology (e.g., SMAD4 status guiding pancreatic cancer prognosis).

  • Hormone signalling efficiency depends on circulation half-life, receptor distribution, and downstream kinase cascades (setting the stage for GPCR, cAMP, and PKC pathways in subsequent lectures).


Practical & Philosophical Takeaways

  • Precision matters: A single phosphorylation event cascade can decide between life, death, or differentiation of a cell.

  • Context matters: The same ligand (TGF-β) may activate or inhibit based on cellular context.

  • Therapeutic angle: Understanding receptor-kinase pathways opens doors to targeted cancer treatments (e.g., kinase inhibitors, monoclonal antibodies against mutated receptors).